The reimbursement adequacy evaluation for the cytomegalovirus (CMV) treatment ‘Livtencity’ has been completed in 1 year since the drug received approval in Korea.

According to industry sources, Takeda Pharmaceuticals Korea submitted its reimbursement application for Liventity (maribavir) in Q3, and the agenda has passed the review of the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 7th of this month. Therefore, the company will now proceed to drug pricing negotiations with the NHIS if the Ministry of Health and Welfare gives the negotiation order.

Whether negotiations will be successful, and a new treatment option will be introduced an